
INCY


Incyte up on positive trial results
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Incyte dropped 10.5% yesterday on FDA drug “rejection”: Here’s what’s actually going on (and why you shouldn’t sell)
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Incyte shares up as stock heads for S&P 500 index
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Incyte is on the way to becoming a complete drug company–or an expensive acquisition candidate
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...Incyte ended the year with news; begins 2017 the same way–and climbs 9.44% on the day
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...Today should be a big day for biotech
JPMorgan Chase holds its big biotech conference today, Monday January 9, and last week’s momentum in the sector as well as likely upbeat guidance to begin the conference at 10:30 a.m. Eastern time from Celgene (CELG) should have the sector on the move.